{"entity":{"id":"idea-cachexia-gdf15-prevention","kind":"idea","name":"Treat cachexia before it starts","aka":[],"tldr":"Cachexia, the muscle wasting driven partly by the hormone GDF-15, kills cancer patients and stops chemotherapy being completed, and late muscle loss is largely irreversible. Ponsegromab, an anti-GDF-15 antibody, reversed weight loss in established cachexia in 2024; the next test is a phase 3 giving it from first-line chemotherapy in pancreatic cancer to prevent wasting rather than treat it.","summary":"This idea proposes treating cachexia before it starts: wasting is a common cause of death in cancer and makes treatment impossible, and now that an effective anti-cachexia drug is in phase 3, the question is whether starting early prevents it. Ponsegromab reversed weight loss in established cachexia (2024), and GDF-15 rises early in pancreatic and lung cancer, so prevention could improve chemotherapy tolerance (Cancer cachexia pathway). The hypothesis is that anti-GDF-15 therapy from diagnosis in high-GDF-15 patients preserves muscle and increases chemotherapy completion and survival, because late muscle loss is largely irreversible. The test is a randomised phase 3 of ponsegromab from first-line chemotherapy in Pancreatic ductal adenocarcinoma; Non-small-cell lung cancer and Gastric cancer are also in scope.","asOf":"2026-09-08","links":[{"label":"Groarke et al., Ponsegromab for the treatment of cancer cachexia (NEJM 2024)","url":"https://doi.org/10.1056/NEJMoa2409515"}],"tags":["mechanism","open-question"],"related":[],"cancers":["pancreatic","nsclc","gastric"],"sections":[],"technologies":["exercise-oncology"],"targets":[],"drugs":[],"companies":[],"institutions":["fred-hutch","cold-spring-harbor"],"pathways":["cachexia-biology","jak-stat"],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hypothesis":"Anti-GDF-15 therapy started at diagnosis in high-GDF-15 patients preserves muscle mass and increases chemotherapy completion and overall survival.","rationale":"Muscle loss is largely irreversible late; GDF-15 is measurable and causal; ponsegromab is safe.","test":"Randomised phase 3 of ponsegromab vs placebo from first-line chemotherapy in metastatic pancreatic cancer with elevated GDF-15, endpoints OS and relative dose intensity.","maturity":"early-clinical"},"route":"/ideas/idea-cachexia-gdf15-prevention/","neighbours":{"cancer":[{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"technology":[{"id":"exercise-oncology","kind":"technology","name":"Exercise & lifestyle oncology","route":"/technologies/exercise-oncology/"}],"institution":[{"id":"cold-spring-harbor","kind":"institution","name":"Cold Spring Harbor Laboratory","route":"/institutions/cold-spring-harbor/"},{"id":"fred-hutch","kind":"institution","name":"Fred Hutchinson Cancer Center","route":"/institutions/fred-hutch/"}],"pathway":[{"id":"cachexia-biology","kind":"pathway","name":"Cancer cachexia","route":"/pathways/cachexia-biology/"},{"id":"jak-stat","kind":"pathway","name":"JAK-STAT signalling","route":"/pathways/jak-stat/"}],"trial":[{"id":"ponsegromab-phase-2","kind":"trial","name":"Ponsegromab phase 2 in cancer cachexia","route":"/trials/ponsegromab-phase-2/"}],"roadmap":[{"id":"nutrition-lifestyle-roadmap","kind":"roadmap","name":"Diet, exercise and lifestyle roadmap: causes established → interventions that disappointed → exercise proven as treatment","route":"/roadmaps/nutrition-lifestyle-roadmap/"}]}}